What’s New With Synergy, Revance, and Sage
Research - Reminder: Our Healthcare Huddle is next Wednesday, Nov 23, at 5:00 ET. We understand that this may conflict with holiday celebrations, so we’ll have a … Continue Reading
PremiumSearch Results for plecanatide
Does The Latest For Linzess Read Through to Synergy?
Research - Synergy Pharma (SGYP) fell briefly this morning when Phase V Research reported that Ironwood’s (IRWD) Linzess (linaclotide) is producing significant rates of adverse events in real world use, and that the drug may even be too dangerous to remain on the market.
PremiumBluebird Bio’s CALD Data, And Other Updates
Research - Bluebird bio (BLUE) released interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) this morning and will present the results at AAN today, evaluating Lenti-D in cerebral adrenoleukodystrophy (CALD), known colloquially as Lorenzo’s Oil disease.
PremiumQuietly Plugging Away, Synergy in 2016
Research - It’s been some time since we’ve revisited Synergy Pharmaceuticals (SGYP). The company continues to guide for phase 3 plecanatide IBS-C data in the first half … Continue Reading
Premium
Catching Up On Biopharma’s Recent Move
Research - The recovery is slowly underway in the land of biotech, and these equities are getting a lift from Pfizer's (PFE) planned merger with Allergan (AGN), announced Monday.
Read now
Bluebird Bio Drops on Patient “Relapse” and Other Biotech Updates
Research - Shares of bluebird bio (BLUE) tumbled 15% mid-day when the company said at a medical conference that a beta-thalassemia patient who received Lentiglobin’s predecessor therapeutic … Continue Reading
Premium
As the Markets Waver, Here’s What We’ve Been Watching
zPremium - Greece unknowns weigh on the market going into the holiday weekend (Happy fourth by the way!), but the referendum on Sunday should offer some perspective … Continue Reading
Premium